`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN INSTITUTIONAL LLC,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`
`Case IPR2020-00324
`Patent 8,114,833
`
`PATENT OWNER’S NOTICE OF DEPOSITION OF
`DR. LAIRD FORREST
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.53, Patent Owner Novo Nordisk A/S (“Patent
`
`Owner”) hereby provides notice that it will conduct cross-examination by
`
`deposition of Dr. Laird Forrest, a witness of Petitioner, Mylan Institutional LLC
`
`(“Petitioner”). The deposition will be conducted by videoconference or other
`
`remote means, and will begin on September 3, 2020 at 9:00 a.m. (unless otherwise
`
`agreed), continuing day to day thereafter until completed. In accordance with 37
`
`C.F.R. § 42.53(d)(1), the parties have conferred and have agreed upon this date and
`
`location for the cross-examination of Dr. Forrest.
`
`The cross-examination will be taken before a Notary Public or other officer
`
`authorized by law to administer oaths. The cross-examination will be recorded by
`
`stenographic and/or audio means. It may also be transcribed by real-time reporting
`
`software and recorded by a videographer.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: August 18, 2020
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`FENWICK &WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`joelke@fenwick.com
`
`Counsel for Novo Nordisk A/S
`
`
`
`
`2
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Notice of Deposition of Dr. Laird Forrest Pursuant to 37 C.F.R. § 42.53
`
`was served on August 18, 2020, by filing this document through the Patent Trial
`
`and Appeal Board End to End system as well as delivering a copy via electronic
`
`mail upon the following attorneys of record for the Petitioner:
`
`Brandon M. White
`Lara Dueppen
`Perkins Coie LLP
`white-ptab@perkinscoie.com
`dueppen-ptab@perkinscoie.com
`liraglutide@perkinscoie.com
`
`Date: August 18, 2020
`
`Respectfully submitted,
`
`/ Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`
`
`Counsel for Novo Nordisk A/S
`
`
`
`
`
`
`
`3
`
`